NasdaqCM:PLSEMedical Equipment
How Pulse Biosciences’ nPulse AFib Refocus Will Impact Pulse Biosciences (PLSE) Investors
In March 2026, Pulse Biosciences, Inc. announced a new focus on accelerating development and future commercialization of its nPulse Cardiac Catheter Ablation System after reporting European feasibility data in Atrial Fibrillation showing high procedural success, durable Pulmonary Vein Isolation, efficient procedure times, and a low rate of serious adverse events.
This shift in capital allocation toward the electrophysiology program, alongside streamlined spending in surgical and soft-tissue...